低血糖症 中国就医指南

Hypoglycemia is a clinical condition characterized by abnormally low blood glucose concentration—typically defined as plasma glucose <70 mg/dL (3.9 mmol/L)—that triggers neurogenic (autonomic) and/or neuroglycopenic symptoms and may impair cognitive function or consciousness if untreated. It is not a disease in itself but a critical metabolic disturbance most commonly associated with diabetes mellitus, especially in patients receiving insulin or insulin secretagogues (e.g., sulfonylureas, meglitinides). Pathophysiologically, hypoglycemia arises from an imbalance between glucose supply (from dietary intake, hepatic glycogenolysis, and gluconeogenesis) and glucose utilization (primarily by brain, muscle, and erythrocytes). In insulin-treated diabetes, exogenous insulin excess relative to carbohydrate intake, physical activity, or declining renal/hepatic function disrupts this balance. Other causes include reactive (postprandial) hypoglycemia, fasting hypoglycemia due to endogenous hyperinsulinism (e.g., insulinoma), adrenal insufficiency, severe liver disease, non-islet cell tumors, critical illness, and certain medications (e.g., quinine, pentamidine, beta-blockers masking symptoms). Epidemiologically, symptomatic hypoglycemia affects ~25–40% of adults with type 1 diabetes annually and ~10–20% of those with insulin-treated type 2 diabetes; severe hypoglycemia (requiring assistance) occurs in ~2–4% of type 1 and ~1–2% of type 2 patients per year. Risk factors include intensive glycemic control, long diabetes duration, impaired awareness of hypoglycemia (IAH), renal impairment, older age, cognitive decline, and socioeconomic barriers to consistent self-monitoring and nutrition access. Hypoglycemia significantly erodes quality of life: recurrent episodes cause anxiety, fear of driving or working, sleep disruption, reduced treatment adherence, social withdrawal, and increased risk of falls, seizures, arrhythmias, and dementia—particularly in older adults. Children may experience developmental delays with frequent severe events. Effective management requires individualized glycemic targets, structured education on carbohydrate counting and insulin adjustment, use of continuous glucose monitoring (CGM) and hybrid closed-loop systems, timely recognition of early symptoms (tremor, sweating, palpitations, hunger), and rapid treatment with 15 g fast-acting carbohydrate followed by retesting. Long-term prevention hinges on identifying and addressing underlying causes, optimizing pharmacotherapy, and empowering patients through shared decision-making and psychosocial support.

# 低血糖症（内分泌科）治疗方案与费用明细

一、非手术/保守治疗方案

• •适用人群：反应性低血糖、药物性低血糖（如胰岛素/磺脲类过量）、功能性低血糖及轻中度症状患者
• •核心措施：饮食调整（少量多餐、高纤维低碳水）、血糖监测、胰岛素剂量优化、糖原分解障碍者补充生糖激素（如氢化可的松）
• •费用明细（单次/疗程）：

- 胰岛素泵调整+教育随访（3个月）：3,500–6,000元 - 激素激发试验（胰高血糖素/胰岛素耐量试验）：800–1,500元 - 基础检验（空腹+餐后血糖、C肽、胰岛素、肝肾功能）：420–680元

二、手术/介入治疗方案

• •适用人群：经影像与生化确诊的胰岛素瘤（单发、局限性）、部分遗传性高胰岛素血症（如ABCC8/KCNJ11突变难控型）
• •核心术式：腹腔镜胰体尾切除术（胰岛素瘤）或局灶性病变精准切除；极少数需开腹探查
• •费用明细（含术前检查）：

- 手术费+麻醉+住院（7–10天）：38,000–65,000元

三、特殊复杂方案

• •耐药/晚期/并发症处理：顽固性高胰岛素血症伴发育迟缓者行二氮嗪联合奥曲肽治疗；难治性胰岛素瘤转移者启用依维莫司靶向治疗（年药费12–24万元）

方案快速选择指南

• •预算≤5,000元/年：首选保守管理+CGM监测+门诊随访
• •疑似器质性病因（反复发作、空腹血糖＜2.8mmol/L）：立即启动激素激发试验+增强影像筛查
• •确诊胰岛素瘤且无转移：优先微创手术（根治率＞95%，复发率＜5%）